ライフサイエンスコーパス: FMT

1 FMT also induced changes in the immune cell populations

2 FMT from a rationally selected donor reduced hospitaliza

3 FMT in patients with blood disorders is safe and promote

4 FMT increased microbial diversity and altered compositio

5 FMT is effective in the eradication of pathogenic antibi

6 FMT protocols involving anaerobic stool processing metho

7 FMT was associated with improved duodenal mucosal divers

8 FMT was associated with lower cure rates in randomized t

9 FMT was safe, but did not induce symptom relief at 12 we

10 FMT with antibiotic pretreatment was well tolerated.

11 FMT-assigned patients underwent repeat endoscopies 4 wee

12 FMT-randomized patients received 5 days of broad-spectru

13 FMT-related adverse events (AE) occurred in 22.3% of cas

14 FMT-TRIM was a 12-week double-blind randomized placebo-c

15 FMT/CT imaging allows quantifying the biodistribution of

16 s (90%); of these, 197 (98%) received only 1 FMT.

17 receive frozen (n = 114) or fresh (n = 118) FMT via enema.

18 on SOC were randomized 1:1 into receiving 15 FMT capsules versus placebo from a single donor enriched

19 s had a total of 11 SAEs compared to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02

20 Patients received either 75 FMT capsules (each capsule contained approximately 0.38

21 were used to treat 31 rCDI patients, with a FMT success rate of 84%.

22 After FMT, 25% of patients with underlying inflammatory bowel

23 erformed on patients' stool before and after FMT and also on donors' stool.

24 gut microbiome composition before and after FMT at the species and strain levels.

25 and colon samples collected before and after FMT treatment from patients who achieved remission compa

26 metabolic changes occurred during and after FMT.

27 n the impairment of intestinal barrier after FMT.

28 Stools from the same patients 15 days after FMT from a healthy donor were also pooled (post-FMT).

29 With a median of 20.5 days after FMT, 8 of 16 (50%) patients developed intestinal coloniz

30 With a median diagnosis at 20.5 days after FMT, 8 of 16 (50%) patients developed intestinal coloniz

31 Antibiotic exposure after FMT independently predicted loss of durability of FMT.

32 76.8% (n=350) had healthcare exposure after FMT.

33 complete ARB decolonization at 1 month after FMT.

34 nd new medical conditions for 6 months after FMT.

35 al supplementation with A. muciniphila after FMT with nonresponder feces restored the efficacy of PD-

36 patients who did not achieve remission after FMT and had increased levels of short-chain fatty acid b

37 Patients in remission after FMT had enrichment of Eubacterium hallii and Roseburia i

38 2.10; range, 0.57-14.29; median score after FMT 1.7; range, 0.71-4.29), urgency (mean reduction, 38%

39 , 0.61; range, 0.00-1.00; median score after FMT, 0.37; range, 0.00-1.00), abdominal pain (mean reduc

40 , 3.88; range, 1.57-5.17; median score after FMT, 2.80; range, 1.14-4.94), flatulence (mean reduction

41 , 3.42; range, 0.71-6.00; median score after FMT, 3.07; range, 0.79-4.23), and quality of life (mean

42 , 3.98; range, 2.13-6.00; median score after FMT, 3.1; range, 951.29-5.90), stool frequency (mean red

43 FMT 32.6; range, 11-119; median score after FMT, 43.1; range, 32.25-99).

44 and fecal samples collected before vs after FMT.

45 d effectiveness outcomes from North American FMT providers.

46 engraftment of donor bacterial groups among FMT recipients, which persisted throughout the 12-week s

47 y issues have hampered the development of an FMT capability at many hospitals.

48 were used to treat 31 rCDI patients, with an FMT success rate of 84%.

49 f total variability for GCL, GCIPL, GCC, and FMT, respectively.

50 itions including nausea, abdominal pain, and FMT-related diarrhea.

51 ncement (MORE), on alpha and theta power and FMT coherence during meditation.

52 e CDI, fidaxomicin for first recurrence, and FMT for subsequent recurrence.

53 al contributions of antibiotic treatment and FMT to the observed results, the data suggest that FMT m

54 FMT National Registry was designed to assess FMT methods and both safety and effectiveness outcomes f

55 e conduct and reporting of studies assessing FMT.

56 Autologous FMT, collected during the weight-loss phase and administ

57 ared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7

58 d with 3 of the 35 (9%) receiving autologous FMT (difference, 23% [95% CI, 4%-42%]; odds ratio, 5.0 [

59 ared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042).

60 the donor FMT group and 2 in the autologous FMT group.

61 Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up fo

62 prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 we

63 composition of the fecal microbiomes before FMT; this might be used to as a biomarker to select pati

64 ife (mean increase, 16%; median score before FMT 32.6; range, 11-119; median score after FMT, 43.1; r

65 cy (mean reduction, 38%; median score before FMT, 0.61; range, 0.00-1.00; median score after FMT, 0.3

66 cy (mean reduction, 13%; median score before FMT, 2.10; range, 0.57-14.29; median score after FMT 1.7

67 ce (mean reduction, 10%; median score before FMT, 3.42; range, 0.71-6.00; median score after FMT, 3.0

68 in (mean reduction, 26%; median score before FMT, 3.88; range, 1.57-5.17; median score after FMT, 2.8

69 rt (mean reduction, 19%; median score before FMT, 3.98; range, 2.13-6.00; median score after FMT, 3.1

70 muscle, and tumor tissue correlated between FMT/CT and PET/MRI.

71 IBS-SSS did not differ between FMT recipients (mean 221 [SD 105]) and placebo recipient

72 nt-refractory IBS with predominant bloating, FMT relieved symptoms compared with placebo (autologous

73 to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02).

74 Subgroup analysis by FMT delivery modality showed lower cure rates with enema

75 bo capsules, or placebo capsules followed by FMT capsules.

76 ompounds, and organ accumulation measured by FMT/CT and PET/MRI correlated significantly with ex vivo

77 h after injection, the mice were measured by FMT/CT and PET/MRI.

78 cystis ST1 and ST3 from donor to patients by FMT.

79 ystis ST1 and ST3 from donors to patients by FMT.

80 iota and brain function in HE after capsular FMT in a randomized, single-blind, placebo-controlled cl

81 primary end point at week 8 following donor FMT maintained remission at 12 months.

82 en 2.0 and 8.0) to weekly healthy lean donor FMT versus placebo capsules for 6 weeks.

83 e either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy

84 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous

85 treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher li

86 ysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24

87 e were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group.

88 s multicenter, retrospective study evaluated FMT safety, effectiveness, and risk factors for failure

89 st, there was no relationship between [(18)F]FMT and methylphenidate-induced [(11)C]raclopride displa

90 vealed a positive correlation between [(18)F]FMT Ki and the baseline (placebo) [(11)C]raclopride meas

91 ) using 6-[(18)F]fluoro-l-m-tyrosine ([(18)F]FMT; a substrate for aromatic amino acid decarboxylase),

92 (n = 3) and patients prior to and following FMT.

93 acid butyrate and pain improvement following FMT.

94 week, after 3 weeks and the months following FMT.

95 k, after 3 weeks, or in the months following FMT.

96 ned in recipients for up to a year following FMT.

97 2011 and 2014 to determine risk factors for FMT failure.

98 opulation and 178 (frozen FMT: n = 91, fresh FMT: n = 87) in the per-protocol population.

99 the frozen FMT group and 85.1% for the fresh FMT group (difference, -1.6% [95% CI, -10.5% to infinity

100 the frozen FMT group and 70.3% for the fresh FMT group (difference, 4.7% [95% CI, -5.2% to infinity];

101 he frozen FMT group and n = 111 in the fresh FMT group) were included in the modified intention-to-tr

102 n-to-treat (mITT) population and 178 (frozen FMT: n = 91, fresh FMT: n = 87) in the per-protocol popu

103 the potential advantages of providing frozen FMT, its use is a reasonable option in this setting.

104 clinical resolution was 75.0% for the frozen FMT group and 70.3% for the fresh FMT group (difference,

105 clinical resolution was 83.5% for the frozen FMT group and 85.1% for the fresh FMT group (difference,

106 total of 219 patients (n = 108 in the frozen FMT group and n = 111 in the fresh FMT group) were inclu

107 However, FMT increased diversity and beneficial taxa.

108 Pre-FMT Candida levels may identify FMT responders.

109 of mycobiota-focused approaches to identify FMT responders prior to therapy initiation.

110 Importantly, FMT from RIP140mvarphiKD to WT not only effectively tran

111 p required hospitalizations compared to 1 in FMT, which was deemed unrelated to FMT.

112 ompared to the placebo group (+5% +/- 12% in FMT group versus -3% +/- 32% in placebo group, mean diff

113 o recipients, this increase was abrogated in FMT recipients.

114 monstrated by 90% relapse-free cure rates in FMT treatment for recurrent Clostridioides difficile inf

115 fied data into an online platform, including FMT protocol, baseline patient characteristics, CDI cure

116 eta power effect sizes) as well as increased FMT coherence relative to those in the control condition

117 zed with ARB were treated with intraduodenal FMT according to a prospective protocol (NCT02461199).

118 bo group were eligible to receive open-label FMT after the double-blind study period.

119 and 8 weeks after the blinded or open-label FMT therapy.

120 linded therapy, and at the end of open-label FMT, if applicable.

121 copic infusion and then intensive multidonor FMT or placebo enemas, 5 d/wk for 8 weeks.

122 Five SOC and no FMT participants developed further HE (P = 0.03).

123 evere AEs occurred in 3.2% of cases, with no FMT-related bacteremia.

124 Weekly administration of FMT capsules in adults with obesity results in gut micro

125 e studies centered around the application of FMT and defined microbial communities as a therapeutic a

126 most important methodological components of FMT and inability to assess the actual conduct of studie

127 Key components of FMT interventions, which are necessary to replicate and

128 ntly associated with decreased durability of FMT [hazard ratio 0.27 (95% CI, 0.15-0.49), p<0.001].

129 We studied the durability of FMT in patients with recurrent CDI.

130 ndependently predicted loss of durability of FMT.

131 postantibiotics are safe, but the effect of FMT without antibiotics using the capsular route require

132 rld study demonstrated high effectiveness of FMT for CDI with a good safety profile.

133 r randomized trial to compare the effects of FMT with those of fidaxomicin and vancomycin.

134 acteriophages mediate many of the effects of FMT, and that FFT might be an alternative approach, part

135 microbiome, underlies some of the effects of FMT.

136 dies are needed to determine the efficacy of FMT for IBS-D.

137 and meta-analysis to assess the efficacy of FMT for recurrent CDI in open-label studies and clinical

138 clinical trial was to assess the efficacy of FMT in alleviating diarrhoea-predominant IBS (IBS-D).

139 ical framework to understand the efficacy of FMT in treating conditions associated with a disrupted g

140 studies assessing the safety or efficacy of FMT.

141 l key factors that determine the efficacy of FMT.

142 despite additional risk factor exposure) of FMT protection is largely unknown.

143 Severe symptoms reported within 1-month of FMT included diarrhea (n = 5 [2%]) and abdominal pain (n

144 the transplanted material on the outcome of FMT.

145 Thirty-eight percent of FMT-driven changes were strain replacements, emphasizing

146 nderstanding of the ecological principles of FMT and have a positive translational impact on the rati

147 t for determining the full safety profile of FMT.

148 The regulation of FMT by the FDA is discussed along with FMT donor screeni

149 MT was associated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval,

150 igilance to define the benefits and risks of FMT across different patient populations are warranted.

151 The primary outcome was safety of FMT compared to SOC using FMT-related serious adverse ev

152 a preclinical demonstration of the safety of FMT in primates infected with a lentivirus, this study p

153 nd use of non-CDI antibiotics at the time of FMT.

154 from a large randomized controlled trial of FMT for ulcerative colitis (UC).

155 In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bac

156 al mouse experiments and a clinical trial of FMT to validate our theoretical framework.

157 was performed to include clinical trials of FMT for CDI.

158 RCTs examined the efficacy of antibiotics or FMT.

159 mized placebo-controlled pilot trial of oral FMT capsules performed at a single US academic medical c

160 Conclusion: In this phase 1 study, oral FMT capsules are safe and well tolerated in patients wit

161 criteria that may help identify personalized FMT donors to more effectively maintain remission in CD

162 Post-FMT, duodenal mucosal diversity (P = 0.01) increased wit

163 se, whereas decreased Candida abundance post-FMT was indicative of ameliorated disease severity.

164 ernatants were created from pre-FMT and post-FMT samples.

165 Sterile pre-FMT and post-FMT supernatants did not affect brain parameters.

166 d on 16 fecal patient samples, pre- and post-FMT, by PCR and subtype (ST) analyses.

167 d on 16 fecal patient samples, pre- and post-FMT, by PCR and subtype (ST) analysis.

168 stantibiotics, but reverted to baseline post-FMT.

169 ated with increased bacterial diversity post-FMT, and the presence of genera was linked to FMT respon

170 neuroinflammation by using samples from post-FMT patients to colonize GF mice shows a direct effect o

171 EncephalApp performance improved post-FMT only (P = 0.02).

172 Reduction in Veillonellaceae were noted post-FMT in sigmoid (P = 0.04) and stool (P = 0.05).

173 from a healthy donor were also pooled (post-FMT).

174 0.02) and serum LBP (P = 0.009) reduced post-FMT.

175 activation in gastrointestinal tissues post-FMT.

176 terial community composition at 2 weeks post-FMT resembled the pre-FMT community structure, although

177 s, which was reduced significantly with post-FMT samples.

178 d as lack of CDI episodes within 1 year post-FMT despite risk factor exposure.

179 Pre-FMT Candida levels may identify FMT responders.

180 Pre-FMT material colonization was associated with neuroinfla

181 High Candida abundance pre-FMT was associated with a clinical response, whereas dec

182 Sterile supernatants were created from pre-FMT and post-FMT samples.

183 High pre-FMT Candida was associated with increased bacterial dive

184 cirrhosis after antibiotics were pooled (pre-FMT).

185 functional redundancy of the recipient's pre-FMT microbiota raises barriers to donor microbiota engra

186 Sterile pre-FMT and post-FMT supernatants did not affect brain param

187 sition at 2 weeks post-FMT resembled the pre-FMT community structure, although differences in the abu

188 re to use an oral vancomycin taper preceding FMT was associated with a significant risk of FMT failur

189 robiota suspension), a commercially prepared FMT drug manufactured using standardized processes and a

190 -generated randomisation sequence to receive FMT capsules followed by identical-appearing placebo cap

191 8 patients were randomly assigned to receive FMT first (n=25) or placebo first (n=23).

192 e randomly assigned to a group that received FMT, applied by colonoscopy or nasojejunal tube, after 4

193 disease outcomes in CD patients who received FMT, and transmission of Bacteroidetes was deleterious.

194 lonic mucosa samples from patients receiving FMT for active UC and stool samples from donors, we asso

195 ociated with remission in patients receiving FMT, and Streptococcus species in donor stool was associ

196 [10%] of the 48 participants while receiving FMT capsules vs four [8%] while receiving placebo), naus

197 However, repeated FMT(s) or additional antibiotics may be needed to optimi

198 A second FMT reduced symptoms in 67% of patients with an initial

199 A second FMT restored the response patients with a prior response

200 ctrum antibiotic pretreatment, then a single FMT enema from the same donor with the optimal microbiot

201 Predictors of failing a single FMT included inpatient status, severe and fulminant CDI,

202 gative C difficile stool test after a single FMT or after subsequent FMT(s) +/- anti-CDI antibiotics,

203 After single FMT, 21% of patients given donor stool reported effects

204 ng 610 patients with CDI treated with single FMT.

205 test after a single FMT or after subsequent FMT(s) +/- anti-CDI antibiotics, respectively.

206 These data suggest FMT is safe in SOT patients.

207 The FDA is committed to ensuring that FMT products can be safely tested in clinical trials.

208 We found that FMT had a significant long-term effect on patient microb

209 the observed results, the data suggest that FMT may have beneficial effects that should be further e

210 Our data suggest that FMT might reduce Candida to contain pro-inflammatory imm

211 The FMT National Registry was designed to assess FMT methods

212 rcentage points) lower in the FMT group; the FMT group also had 14 fewer days of hospitalization (CI,

213 +/- 6.7 kg/m2 and 41.3 +/- 5.1 kg/m2 in the FMT and placebo groups, respectively.

214 Five patients in the FMT group and 40 in the antibiotic group developed BSI.

215 t improvements in insulin sensitivity in the FMT group compared to the placebo group (+5% +/- 12% in

216 Patients in the FMT group received blended homogenized stool from 3-7 un

217 e participants were lost to follow-up in the FMT group.

218 CI, 10 to 35 percentage points) lower in the FMT group; the FMT group also had 14 fewer days of hospi

219 Cognition improved in the FMT, but not the SOC, group.

220 f important methodological components of the FMT intervention.

221 ning, stool preparation, and delivery of the FMT.

222 Furthermore, screening the FMT donor stool for antibiotic resistance revealed 21 po

223 een shown to modulate frontal midline theta (FMT) and alpha oscillations that are linked with marked

224 l complex (GCC), and full macular thickness (FMT) were exported.

225 relate to recovery from C. difficile through FMT therapy.

226 be beneficial to transmit/eliminate through FMT, and provide criteria that may help identify persona

227 tients, and fully characterized according to FMT standards.

228 MT, and the presence of genera was linked to FMT responsiveness.

229 ts tested negative for Blastocystis prior to FMT.

230 tients tested Blastocystis negative prior to FMT.

231 1%) had hospitalizations possibly related to FMT.

232 5, p = 0.09), and no serious AEs related to FMT.

233 wever, only a subset of patients responds to FMT, and there is a pressing need for biomarkers of resp

234 al (CI) 72.7%-84.0%] had durable response to FMT at one year.

235 jority of patients had a durable response to FMT despite exposure to CDI risk factors.

236 Durable response to FMT was defined as lack of CDI episodes within 1 year po

237 nor stool was associated with no response to FMT.

238 d to 1 in FMT, which was deemed unrelated to FMT.

239 f advanced fluorescence-mediated tomography (FMT)/CT in comparison to PET/MRI for quantitative analys

240 tected by fluorescence molecular tomography (FMT) combined with micro-computed tomography (CT).

241 Fecal microbial transplant (FMT) after antibiotics improves outcomes in HE, but the

242 Fecal microbial transplant (FMT) enemas postantibiotics are safe, but the effect of

243 esponded best to fecal microbial transplant (FMT).

244 r strategy to a fecal microbiota transplant (FMT) donor stool using multiple growth media, and found

245 Fecal microbiota transplant (FMT) is a highly efficacious treatment for recurrent CDI

246 Fecal microbiota transplant (FMT) is recommended for Clostridium difficile infection

247 Fecal microbiota transplant (FMT) reverses the course of otherwise lethal sepsis by e

248 Fecal microbiota for transplantation (FMT) is being studied as a potential intervention for nu

249 concurrent fecal microbiome transplantation (FMT).

250 ibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 pa

251 fficacy of fecal microbiota transplantation (FMT) as a potential therapeutic in HIV-infected individu

252 ction with fecal microbiota transplantation (FMT) at a tertiary referral center between 2011 and 2014

253 Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative co

254 eekly oral fecal microbiota transplantation (FMT) capsules from healthy lean donors and their ability

255 Fecal microbiota transplantation (FMT) could be a novel treatment option for several chron

256 sized that fecal microbiota transplantation (FMT) could be used to eradicate ARB in humans.

257 -into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we we

258 rence, and fecal microbiota transplantation (FMT) for subsequent recurrence (strategy 44) cost an add

259 Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into ger

260 y prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcera

261 ization of fecal microbiota transplantation (FMT) has jump-started over the past two decades.

262 Faecal microbiota transplantation (FMT) has shown promise in alleviating the symptoms of ir

263 ponsive to fecal microbiota transplantation (FMT) have reduced phages compared to non-responders, and

264 Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent CDI, ye

265 ND & AIMS: Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostri

266 ta through fecal microbiota transplantation (FMT) is a promising approach for the treatment of CD.

267 Fecal microbiota transplantation (FMT) is a promising, but not readily available, interven

268 Fecal microbiota transplantation (FMT) is an emerging therapy for recurrent or refractory

269 Fecal microbiota transplantation (FMT) is highly effective for preventing recurrent Clostr

270 Fecal microbiota transplantation (FMT) is highly effective for treating recurrent Clostrid

271 Fecal microbiota transplantation (FMT) is more effective than antibiotics in treating recu

272 Fecal microbiota transplantation (FMT) is recommended for treatment of recurrent Clostridi

273 Fecal microbiota transplantation (FMT) is used commonly for treatment of Clostridioides di

274 Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it has not been stu

275 effect of fecal microbiota transplantation (FMT) on obesity, and plasma glucose.

276 eated with fecal microbiota transplantation (FMT) provided by healthy donors.

277 robiota as fecal microbiota transplantation (FMT) rescues antibiotic-associated depletion of IL-33.

278 Fecal microbiota transplantation (FMT) targeting gut microbiota has recently been successf

279 open-label fecal microbiota transplantation (FMT) therapy in patients with predominant abdominal bloa

280 s and that fecal microbiota transplantation (FMT) would reduce the number of antibiotic-resistant gen

281 m, such as fecal microbiota transplantation (FMT), are being developed as therapeutic interventions.

282 studies of fecal microbiota transplantation (FMT), finding that high functional redundancy of the rec

283 eated with fecal microbiota transplantation (FMT), using feces provided by healthy donors.

284 iotics, or fecal microbiota transplantation (FMT).

285 A retrospective study of adults undergoing FMT for recurrent CDI was conducted.

286 Patients undergoing FMT in clinical practices across North America were elig

287 bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were

288 Ninety-four SOT patients underwent FMT, 78% for recurrent CDI and 22% for severe or fulmina

289 We confirmed using FMT from HFD-fed RIP140mvarphiKD to wild type (WT) mice

290 come was safety of FMT compared to SOC using FMT-related serious adverse events (SAEs).

291 antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so.

292 We aimed to define whether FMT using a rationally derived stool donor is safe in re

293 on of FMT by the FDA is discussed along with FMT donor screening and manufacturing considerations.

294 may be needed to optimize rates of cure with FMT.

295 Of the 290 patients, 109 were treated with FMT and 181 received antibiotics.

296 Patients treated with FMT and those treated with antibiotics were matched on p

297 of differences in the patients treated with FMT versus antibiotics in many baseline characteristics,

298 rt, patients with recurrent CDI treated with FMT were less likely to develop primary BSI.

299 Notably, treatment with FMT was associated with favorable changes in immune cell

300 ctive safety data are limited and real-world FMT practice and outcomes are not well described.